Treatment with the pan-BET protein inhibitor I-BET151 led to a broad reduction in H3K27ac levels, disrupted RUNX1 driven pathogenic super-enhancers, and down-regulated key RUNX1 and NOTCH1 target genes and proliferation of T-ALL cell lines. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.